Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy Trial will be conducted as a collaboration between Genelux and The...

Genelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions First two patients dosed in Phase 1b Trial in Ovarian Cancer at Florida Hospital Cancer Institute (FHCI) First three patients dosed in Phase 1b Trial in Solid Organ Cancers at Moores Cancer Center at...

Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma Data Demonstrate Favorable Safety Profile and Anti-Tumor Activity Results to be Presented at ASCO Annual Meeting 2015 During Two Poster Presentations SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) --...

Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015 SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced...